Apolipoprotein A-1
The main structural protein of HDL particles — a direct count of your HDL particles, the way ApoB counts atherogenic ones.
The ApoB:ApoA-1 ratio is one of the strongest lipid predictors of heart attack risk in large international data (INTERHEART). Particularly relevant to anyone using androgens, which suppress HDL hard.
Check a Apolipoprotein A-1 result against this range →
What Apolipoprotein A-1 actually measures — the analyte, and the assay
The analyte is apolipoprotein A-I: 243 amino acids, about 28 kDa, the main structural protein of HDL and the activator of the enzyme that esterifies cholesterol inside the particle. It is measured by immunoturbidimetry against an international reference preparation, which makes it, like apoB, a directly measured and reasonably transferable number rather than a calculated one.
One correction has to come first, because it is made almost everywhere including on the rest of this site: apoA-I is not a count of your HDL particles. ApoB works as a particle count because exactly one molecule sits on each atherogenic particle and never leaves. ApoA-I does not behave that way at all — it is an exchangeable apolipoprotein that transfers between particles, and a single HDL particle typically carries several copies, with the number varying by particle size and maturation state. So apoA-I measures the total pool of a protein, not the number of the things it rides on. The symmetry with apoB is rhetorical, not structural.
What the measurement is genuinely good for is the ratio. The case-control study that identified a common set of modifiable risk factors for myocardial infarction across 52 countries used the apoB-to-apoA-I ratio as its lipid variable Yusuf 2004, and that is the context in which most readers have met this test. Comparisons of apoB, LDL-C and non-HDL-C as risk markers continue to find the apoB-containing side of the ratio doing the work Sehayek 2025.
Fasting is not required, for the same reason it is not required for apoB: a meal loads existing particles rather than changing how many there are Nordestgaard 2016.
Apolipoprotein A-1: what changes the blood, and what only changes the reading
What changes the apolipoprotein A-I in your blood:
- Androgens. The largest and fastest suppressor in the population this site is written for, and oral 17-alpha-alkylated compounds do it hardest. The fall is real biology, not a measurement effect.
- Insulin resistance and visceral adiposity, which lower apoA-I while raising triglycerides — the same coupling that produces apoB discordance in this phenotype Sniderman 2024.
- Inflammation and acute illness. ApoA-I is a negative acute-phase reactant: it falls during infection, after surgery and after a myocardial infarction, and takes weeks to return. A value drawn in hospital is not that person's baseline.
- Alcohol, which raises it — one of the reasons a 'favorable' apoA-I is not automatically good news.
- Estrogen, which raises it; aerobic training, which raises it modestly; smoking, which lowers it.
- Genetics — variants in APOA1 itself and in the ABCA1 and LCAT pathways produce low concentrations that have nothing to do with lifestyle and do not carry the same meaning.
What changes only the reading:
- Lipemia and paraproteins, which distort turbidimetric assays generally.
- Being measured during an acute-phase response, which is listed above as biology and belongs here too: the protein really did fall, and it is not telling you anything about cardiovascular risk while it is down.
- The ratio's own arithmetic. An apoB-to-apoA-I ratio inherits the imprecision of two assays at once, so a change in the ratio can be produced by movement in either component — and the two components have very different clinical weight.
Reference interval or decision threshold — which kind of number Apolipoprotein A-1 is
The apoA-I number is a reference interval; the ratio is a risk threshold; and neither is a treatment target. That third clause is the one this page has to carry, and it is why an 'optimal' apoA-I is harder to defend than an optimal apoB.
The printed interval is the central 95% of a laboratory's reference population, which makes it distributional in exactly the ordinary sense. The ratio thresholds come from cohort and case-control data, of which the 52-country study is the best known Yusuf 2004 — those are outcome-derived and legitimate as risk stratification.
What does not exist is evidence that moving apoA-I moves the outcome. The trials that raised HDL cholesterol pharmacologically did not reduce events, and the field's response has been to stop treating HDL as a quantity and start measuring what it does: the shift from simple quantity measurement to functional quality assessment is now the organizing idea of the HDL literature Thakkar 2021, and a cell-free assay of HDL-specific phospholipid efflux has been shown to predict incident cardiovascular disease Sato 2023. A target apoA-I of 140 or 150 mg/dL is a number nobody has anchored to an outcome by intervention. Read it as a description of your metabolic state, not as a dial.
How you would know your Apolipoprotein A-1 was wrong — and when to redraw
Retest it with apoB, on the same draw, six to eight weeks after anything changes. The ratio is the point of the test, and measuring the two halves on different days introduces variation that has nothing to do with the patient. The six-to-eight-week window is inherited from the apoB side, where particle kinetics set it.
Conditions that must match: the same laboratory; at least four to six weeks clear of illness, injury or surgery, because of the negative acute-phase behavior described above; a stable alcohol intake, which is the most commonly overlooked confounder on this specific marker; a stable weight; and, for anyone using androgens, the same point in the same protocol.
What would have to change for the retest to mean something. ApoA-I should move with HDL cholesterol. If apoA-I has fallen and HDL-C has not, look at the specimen and the timing before believing it. And since the ratio is what carries the risk information, a ratio that improved because apoA-I rose is a weaker result than one that improved because apoB fell — only the second corresponds to an intervention with outcome evidence behind it Sniderman 2024.
How you would know the value was wrong. A low apoA-I drawn within weeks of an infection or an operation should simply be repeated once recovered; the acute-phase fall is large enough to reclassify somebody. A very low apoA-I in a healthy, lean, non-drinking person with a normal apoB is not an artifact to dismiss but a reason to look for a genetic cause, and the confirmatory step is a full lipid panel plus family history rather than a repeat.
What Apolipoprotein A-1 cannot tell you
It is not a particle count, for the exchangeability reason given above. Anyone using it as the HDL mirror image of apoB is using the wrong mental model.
It cannot tell you whether your HDL works. Concentration and function are different quantities, and the functional measures — cholesterol efflux, phospholipid efflux — carry predictive information that the concentration does not Thakkar 2021 Sato 2023. Neither functional assay is available as a routine clinical test, which is a limitation worth knowing rather than a reason to over-read the one that is.
Raising it has not been shown to help anyone. This is the single most important limitation and it separates apoA-I from apoB completely: one side of the ratio has a therapeutic literature behind it and the other does not Sehayek 2025.
A high apoA-I does not offset a high apoB. The ratio is a summary statistic and it can be improved by a change in the harmless half. Two people with the same ratio and very different apoB do not have the same risk Sniderman 2024.
The wrong inference readers actually draw is that a strong apoA-I is protection they have earned and can bank against a rising apoB. It is better read as a readout of insulin sensitivity, inflammation, alcohol intake and hormonal state — four things worth knowing, none of which is a shield.
Sources read for these sections
- Yusuf S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004 · PMID 15364185
- Thakkar H, et al. Changing Perspectives on HDL: From Simple Quantity Measurements to Functional Quality Assessment. Journal of Lipids 2021 · PMID 33996157
- Sato M, et al. Cell-free, high-density lipoprotein-specific phospholipid efflux assay predicts incident cardiovascular disease. Journal of Clinical Investigation 2023 · PMID 37471145
- Sniderman AD, et al. Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention. European Heart Journal 2024 · PMID 38700053
- Nordestgaard BG, et al. Fasting is not routinely required for determination of a lipid profile. European Heart Journal 2016 · PMID 27122601
- Sehayek D, et al. ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk. Journal of Clinical Lipidology 2025 · PMID 40681368
The plan of attack
In this order. Most people start at step four, which is why they change five things at once and learn nothing.
- Confirm the number is real
Androgens, and estrogen in the other direction. Testosterone lowers ApoA1; estrogen raises it. Both are real drug effects rather than changes in cardiovascular risk of the same size. Record your hormone status on the result — otherwise a low ApoA1 on TRT reads as a risk finding rather than a drug effect. - Read it with its partner
Non-fasting acceptable. Draw it alongside: ApoB (Apolipoprotein B), Lipid Panel (Cholesterol, HDL, LDL, Triglycerides), hs-CRP (High-Sensitivity C-Reactive Protein). - Work out which direction is yours
If it's high — Generally favorable.
If it's low — Reduced reverse cholesterol transport and elevated cardiovascular risk — the classic androgen-user profile. - Fix it in this order
Nutrition. Olive oil and monounsaturated fats, oily fish, reduce refined carbohydrate and trans fats.
Lifestyle. Aerobic exercise is the most reliable HDL/ApoA-1 raiser. Stop smoking, lose visceral fat.
Supplements. Omega-3s, niacin (raises HDL but no proven outcome benefit). Honestly, exercise beats every supplement here.
Hormones. Minimize oral androgens — they are uniquely damaging to HDL. Injectables are far gentler. Estrogen raises ApoA-1 (part of why premenopausal women have lower cardiovascular risk).
Compounds. Run this alongside ApoB if you're on androgens — the ratio tells you far more than either alone.
Work down the list, not across it. Adding a compound on top of an unfixed diet is why generic protocols fail. - Retest
Every 3–6 months on androgens. Change one thing at a time, or the retest can't tell you which thing worked.
How to fix it
📚 Yusuf S et al., Lancet 2004 (INTERHEART) — ApoB:ApoA-1 as the strongest lipid risk predictor across 52 countries.
This page can tell you what could have made your Apolipoprotein A-1 wrong. It cannot tell you whether it did.
Everything above is free and stays free — the assay, what changes the reading rather than the blood, the retest window and the sources. What no page can do is look at your draw: which laboratory ran it, at what hour, what you were taking that week, and what else was flagged beside it. Every one of those changes the answer, and none of them is on any page. Bringing a real result to people who know that list is what the members' area is for.
Bring your result — $10/mo →🩸 Test your Apolipoprotein A-1
Order directly through Marek Diagnostics — no doctor's visit needed, drawn at any Quest location in the US. Code CAMERON applies 10% off automatically.
Order this test — 10% off → Browse all 103 markers →What Apolipoprotein A-1 is usually tested alongside
One marker is a data point. These panels add the markers that make Apolipoprotein A-1 interpretable, name why each is on the list, and load the set into your cart at 10% off.
includes this + 8 more markers — Anyone over 30, anyone with a family history of early heart disease, or anyone who's been told their cholesterol is 'fine' and wants to know what that actually means.
What people use Apolipoprotein A-1 to decide
Nobody orders a test for its own sake. Apolipoprotein A-1 is on the test list for these pathways — each one links to what the pathway claims, and what its test list is read for before you spend anything on it.
ApoB counts atherogenic particles; LDL-C estimates the cholesterol inside them. When the two disagree — common in insulin resistance — ApoB is right and LDL-C is falsely reassuring.
Would you feel it? Symptoms Apolipoprotein A-1 helps explain
People search for how they feel, not for a marker. These are the complaints where this one is worth checking, and whether it is first-line or a follow-up.
Why your Apolipoprotein A-1 might be wrong
Most abnormal results are interference, not disease. Check these before you change anything. Each says whether the number is wrong (repeat it), badly timed (redraw it), or real with a cause.
Testosterone lowers ApoA1; estrogen raises it. Both are real drug effects rather than changes in cardiovascular risk of the same size.
Record your hormone status on the result — otherwise a low ApoA1 on TRT reads as a risk finding rather than a drug effect.
This is an acute-phase reactant — it moves substantially during any infection, injury or inflammatory episode, and the change has nothing to do with your baseline.
Wait two weeks after any illness, vaccination or injury before drawing or interpreting.
What Apolipoprotein A-1 means in combination
One marker tells you a little; combinations tell you the story. These are the named patterns this one takes part in.
The single most under-monitored consequence of androgen use. Androgens — especially oral 17-alpha-alkylated compounds — suppress HDL dramatically and raise ApoB. There are no symptoms; the cost is cumulative arterial damage measured in decades.
Prefer injectables over orals and minimize oral duration. Add cardio, soluble fiber, omega-3s. Many long-term users treat ApoB pharmacologically (statin/ezetimibe) with a physician — that's a rational trade if you're committed to being on hormones for years. Track ApoB every 3 months, not just a standard lipid panel.
What to test next
These put Apolipoprotein A-1 in context — each with its own full breakdown.
Frequently asked questions
94–178 mg/dL. Ranges vary by laboratory and assay — always compare to the range printed on your own report.
>140 mg/dL, with an ApoB:ApoA-1 ratio <0.6 (lower is better).
Generally favorable.
Reduced reverse cholesterol transport and elevated cardiovascular risk — the classic androgen-user profile.
You can order Apolipoprotein A-1 directly through Marek Diagnostics without a doctor's visit — drawn at any Quest Diagnostics location in the US. Code CAMERON applies 10% off automatically.
Where this goes next
This page is the free framework. The protocol itself — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.